Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 10/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.38 |
| ▸ | PRKCA | P17252 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8968518 | 0.92 | PRKCQ (0.47) | PRKCQPRKCDPRKCAALDH1A1RPS6KB1 | |
| SCHEMBL8968269 | 0.90 | PRKCQ (0.49) | GSK3BPRKCQPRKCDPRKCAALDH1A1 | |
| SCHEMBL8968285 | 0.90 | PRKCQ (0.49) | GSK3BPRKCQPRKCDPRKCAALDH1A1 | |
| SCHEMBL8968114 | 0.90 | PRKCQ (0.49) | GSK3BPRKCQPRKCDPRKCAALDH1A1 | |
| SCHEMBL8968932 | 0.87 | PRKCQ (0.42) | GSK3BPRKCQPRKCDPRKCAALDH1A1 | |
| SCHEMBL8968438 | 0.86 | PRKCQ (0.45) | GSK3BPRKCQPKMPRKCDPRKCA | |
| SCHEMBL9010329 | 0.85 | PRKCQ (0.59) | GSK3BPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL15930711 | 0.83 | PRKCQ (0.55) | GSK3BPRKCQPKMPRKCDPRKCA | |
| SCHEMBL9012860 | 0.80 | PRKCQ (0.61) | PRKCQPRKCDPRKCARPS6KB1PRKCB | |
| SCHEMBL8967599 | 0.79 | PRKCQ (0.56) | PRKCQPRKCDPRKCAALDH1A1PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | GSK3B 152/4885PRKCQ 38/4885PKM 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.